XyloCor Therapeutics

Healthcare & Life Sciences

Recent Finacing

Series B

Recent Raise

$67.5M

XyloCor Therapeutics develops gene therapies for cardiovascular diseases, focusing on treatments for refractory angina and coronary artery bypass graft surgery.

Total Funding

$67.5M

Headquarters

King of Prussia, USA

Founded

N/A

Website

xylocor.com

Focus Areas

Gene therapy

Cardiovascular diseases

Clinical trials

Refractory angina

Coronary artery bypass

Blood vessel growth

Investors